2015
DOI: 10.1089/apc.2015.0240
|View full text |Cite
|
Sign up to set email alerts
|

Hepatitis C Direct Acting Antiviral Therapies in a New York City HIV/AIDS Special Needs Plan: Uptake and Barriers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
7
0

Year Published

2017
2017
2019
2019

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(7 citation statements)
references
References 12 publications
0
7
0
Order By: Relevance
“…24 In 2 separate studies evaluating much smaller cohorts of HIV/HCV coinfected patients, DAA treatment uptake was 14% and 6% over time periods similar to the VA report. 29,30…”
Section: Discussionmentioning
confidence: 99%
“…24 In 2 separate studies evaluating much smaller cohorts of HIV/HCV coinfected patients, DAA treatment uptake was 14% and 6% over time periods similar to the VA report. 29,30…”
Section: Discussionmentioning
confidence: 99%
“…These organizational constraints (e.g., prior authorizations) may themselves pose barriers to medical evaluation completion and care continuum progress (40, 52, 53). Similarly, providers, in response to guidelines or unconscious biases, differentially apply “eligibility criteria” in ways that constituting a “stutter-step” in health-care provision, and introducing health disparities (25, 51).…”
Section: Resultsmentioning
confidence: 99%
“…For example, the HIV continuum does not convey the fact that many people are diagnosed late in the course of their infection (52). It also does not convey the timeliness of linkages to care or of achieving viral suppression.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…This may be indicative of a provider-level and/or systematic bias relating to medication adherence, AIDS status, and HIV-1 RNA viral load; providers may have been limiting care to “ideal patients” as determined by payers and government agencies. 24,25 In addition, health beliefs, stigma and medication, and appointment adherence have been shown to be strongly associated with engagement in HCV care. 2628 However, these barriers were often seen before the era of DAA medications.…”
Section: Discussionmentioning
confidence: 99%